Latest filing published 28 Jun 2024 for Aridis Pharmaceuticals, Inc..
Insider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
Eric Patzer: trading record in brief
Eric Patzer, listed as board member, appears in our data through filings on Aridis Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 22 December 2020 to 24 June 2024, the count stands at 4 filings.
The open-market record is one-sided, with 2 purchases worth €68k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 option exercise. Since January 2024: 1 purchase and no sales on the market.
The newest entry dates from 28 June 2024: an open-market purchase of €47k, in Aridis Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 10 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Eric Patzer
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 714,286 shares@ €0.065268.7% of flowCommon stock purchaseSEC:0001493152-24-025672:0Canonical exit: 22 Sept 2024 (T+90)
- 12,000 sharesCommon StockSEC:0001493152-23-021487:0
- 5,175 shares@ €4.093731.3% of flowCommon StockSEC:0001104659-21-096531:0Canonical exit: 25 Oct 2021 (T+90)
3 of 3 declarations